Hydroxyurea for Children and Adults with Hemoglobin SC Disease.
Authors
Dei-Adomakoh YA, Segbefia CI, Latham TS, Lane AC, Dzefi-Tettey K, Amissah-Arthur K, Corquaye O, Korang L, Mensah E, Ekpale P, Ghunney W, Tagoe LG, Oteng A, Amoako E, Schandorf E, Bankas E, Awuku NA, Seedah D, Stuber SE, Smart LR, Ware RE
Abstract
Hemoglobin SC (HbSC) is a common sickle hemoglobinopathy that causes acute complications, chronic organ damage, and early death with no established disease-modifying treatment. In this trial, we examined the safety and efficacy of hydroxyurea treatment in patients with HbSC.
This website or its third-party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the IASP Privacy Policy. By closing this banner, you agree to the use of cookies.Agree
